1 option
Pricing in the Market for Anticancer Drugs / David H. Howard, Peter B. Bach, Ernst R. Berndt, Rena M. Conti.
- Format:
- Book
- Author/Creator:
- Howard, David H.
- Series:
- Working Paper Series (National Bureau of Economic Research) no. w20867.
- NBER working paper series no. w20867
- Language:
- English
- Physical Description:
- 1 online resource: illustrations (black and white);
- Place of Publication:
- Cambridge, Mass. National Bureau of Economic Research 2015.
- Summary:
- Drugs like bevacizumab ($50,000 per treatment episode) and ipilimumab ($120,000 per episode) have fueled the perception that the launch prices of anticancer drugs are increasing over time. Using an original dataset of 58 anticancer drugs approved between 1995 and 2013, we find that launch prices, adjusted for inflation and drugs' survival benefits, increased by 10%, or about $8,500, per year. Although physicians are not penalized for prescribing costly drugs, they may be reluctant to prescribe drugs with prices that exceed subjective standards of fairness. Manufacturers may set higher launch prices over time as standards evolve. Pricing trends may also reflect manufacturers' response to expansions in the 340B Drug Pricing Program, which requires manufacturers to provide steep discounts to eligible providers.
- Notes:
- Print version record
- January 2015.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.